Mycophenol acid in ocular automimmune disorders - Can we optimise this therapy?;Ein beitrag zur anwendung von mycophenolsäure bei autoimmunerkrankungen des auges: Können wir die therapie optimieren?

Klinische Monatsblatter fur Augenheilkunde

Volumn 225, Issue 1, 2008, Pages 66-69

  Pleyer, Uwe ^a   Ruokonen, P ^a   Schmidt, N ^a   Feist, E ^a   Hohne M ^b   Stanojlovic, S ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Novartis Pharma

Author keywords

Cornea; Intraocular inflammation; Pharmacology; Uveitis

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG EFFECT; EYE DISEASE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OCULAR AUTOIMMUNE DISORDER; QUESTIONNAIRE; UVEITIS;

EID: 39149088329     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027134     Document Type: Article

References (18)

1. Bertelmann E, Reinhard T, Pleyer U. Stand der Immunprophylaxe und -therapie bei perforierender Keratoplastik. Eine Umfrage bei Mitgliedern der Sektion Kornea der DOG. Ophthalmologe 2003; 100: 1031-1035
2. Budde K, Glander P, Diekmann F et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004; 5: 1333-1345
3. Chan L, Mulgaonkar S, Walker R et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Clin Nephrol 2006; 66: 103-111
4. Dumortier J, Gagnieu MC, Salandre J et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study. Liver Transpl 2006; 12 (9): 1342-1346
5. Ginsburg PM, Thuluvath PJ. Diarrhea in liver transplant recipients: etiology and management. Liver Transpl 2005; 11: 881-890
6. Greiner K, Varikkara M, Santiago C et al. Efficienz von Mycophenolat-Mofetil bei der Therapie der intermediären und posterioren Uveitis. Ophthalmologe 2002; 99: 691-694
7. Hummel M, Yonan N, Ross H et al. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clin Transplant 2007; 21: 18-23
8. Kamar N, Oufroukhi L, Faure P et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium. Nephrol Dial Transplant 2005; 20: 2231-2236
9. Kleinman L, Faull R, Walker R et al. Gastrointestinal-specific patient-reported outcome instruments differentiate between renal transplant patients with or without GI complications. Transplant Proc 2005; 37: 846-849
10. Knapp S, Bertelmann E, Hartmann C et al. Intraocular availability of topically applied mycophenolate mofetil in rabbits. J Ocul Pharmacol Ther 2003; 19: 191-192
11. Larkin G, Lightman S. Mycophenolate Mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999; 106: 370-374
12. Legendre C, Cohen D, Zeier M et al. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies. Transplant Proc 2007; 39: 1386-1391
13. Murphy CC, Greiner K, Plskova J et al. Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. Br J Ophthalmol 2007; 91: 154-156
14. Pelletier RP, Akin B, Henry ML et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200-205
15. Pescovitz MD, Conti D, Dunn J et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant 2000; 14: 179-188
16. Reis A, Reinhard T, Voiculescu A et al. Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol 1999; 83: 1268-1271
17. Siepmann K, Huber M, Stübiger N et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006; 244: 788-794
18. Zakliczynski M, Trybunia D, Nozynski J et al. Elective conversion from CellCept to Myfortic under control of mycophenolic acid concentration in stable heart transplant recipients. J Heart Lung Transplant 2007; 26: 303-304